Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DBVT

DBV Technologies ADR

Sep 06 • 04:00PM ET

0.8001

Dollar change -0.0059
Percentage change -0.73	%

Healthcare • Biotechnology • France • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: APIE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	1.86%	Shs Outstand	96.21M	Perf Week	-10.00%
Market Cap	76.97M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	0.80%	Shs Float	94.41M	Perf Month	-13.97%
Income	-88.38M	PEG	-	EPS next Q	-0.35	Inst Own	15.93%	Short Float	0.31%	Perf Quarter	-29.44%
Sales	0.00M	P/S	-	EPS this Y	-6.80%	Inst Trans	57.77%	Short Ratio	4.60	Perf Half Y	-51.57%
Book/sh	0.82	P/B	0.97	EPS next Y	54.72%	ROA	-53.29%	Short Interest	0.29M	Perf Year	-75.75%
Cash/sh	0.69	P/C	1.16	EPS next 5Y	21.22%	ROE	-72.64%	52W Range	0.50 - 3.52	Perf YTD	-58.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.36%	ROI	-102.92%	52W High	-77.27%	Beta	0.69
Dividend TTM	-	Quick Ratio	3.29	Sales past 5Y	0.00%	Gross Margin	-	52W Low	59.26%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	3.29	EPS Y/Y TTM	14.69%	Oper. Margin	0.00%	RSI (14)	34.23	Volatility	11.48% 6.89%
Employees	104	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.20	Target Price	3.67
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	-33.97%	Payout	-	Rel Volume	0.71	Prev Close	0.81
Sales Surprise	-28.70%	EPS Surprise	23.89%	Sales Q/Q	-	Earnings	Jul 30 AMC	Avg Volume	63.89K	Price	0.80
SMA20	-11.40%	SMA50	-9.70%	SMA200	-41.02%	Trades		Volume	45,183	Change	-0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-23	Upgrade	Societe Generale	Hold → Buy
Dec-16-22	Downgrade	Goldman	Neutral → Sell
May-10-22	Downgrade	Goldman	Buy → Neutral	$6 → $1.50
Sep-14-21	Upgrade	Societe Generale	Hold → Buy
Jan-22-21	Downgrade	Societe Generale	Hold → Sell
Nov-02-20	Upgrade	Societe Generale	Sell → Hold
Aug-06-20	Downgrade	Societe Generale	Buy → Sell
Aug-05-20	Reiterated	H.C. Wainwright	Buy	$25 → $14
Mar-17-20	Downgrade	Stifel	Buy → Hold	$18 → $6
Jan-09-20	Upgrade	Stifel	Hold → Buy	$10 → $18
Dec-16-19	Initiated	Citigroup	Buy
Sep-05-19	Resumed	Morgan Stanley	Equal-Weight
Jun-17-19	Initiated	Goldman	Buy
Dec-20-18	Downgrade	Stifel	Buy → Hold
Dec-20-18	Downgrade	Jefferies	Buy → Hold
Dec-20-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-20-18	Downgrade	Barclays	Overweight → Equal Weight
Oct-31-17	Upgrade	Societe Generale	Sell → Hold
Oct-24-17	Downgrade	Societe Generale	Buy → Sell
Oct-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight

Show Previous Ratings

Sep-04-24 04:30PM	DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.63%
Aug-02-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (GlobeNewswire)
Jul-30-24 08:55PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:30PM	DBV Technologies Announces Filing of 2024 Half-Year Report ? Conditions for Accessing or Consulting the Report (GlobeNewswire)
04:30PM	DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results (GlobeNewswire)
01:30AM	Loading…
Jul-29-24 01:30AM	DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 (GlobeNewswire)
Jul-08-24 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jun-05-24 04:30PM	DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (GlobeNewswire)
May-31-24 09:51AM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
May-30-24 04:30PM	DBV Technologies to Participate in Upcoming EAACI 2024 Congress (GlobeNewswire)
May-17-24 04:30PM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire) +7.97%
May-16-24 04:30PM	DBV Technologies Announces Results of its 2024 Combined General Meeting (GlobeNewswire)
May-09-24 04:30PM	DBV Technologies to Participate in Upcoming Investor Conferences (GlobeNewswire) -17.77%
May-07-24 11:53PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:30PM	Loading…
04:30PM	DBV Technologies Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Apr-25-24 04:30PM	Combined General Meeting of May 16, 2024 (GlobeNewswire)
Apr-04-24 04:43PM	Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (GlobeNewswire) -6.67% +10.00%
Mar-08-24 11:01AM	DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:33AM	DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document (GlobeNewswire)
Mar-07-24 10:52PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:30PM	DBV Technologies Reports Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Mar-04-24 04:30PM	DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 (GlobeNewswire)
Feb-20-24 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2024 Congress (GlobeNewswire) -7.58%
Jan-16-24 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Dec-04-23 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (GlobeNewswire) -5.79% +6.21%
Nov-09-23 04:30PM	DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin Peanut in Toddlers (GlobeNewswire) -5.66%
Nov-06-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (GlobeNewswire)
Nov-02-23 04:30PM	DBV Technologies to Present New Data at ACAAI 2023 (GlobeNewswire)
Oct-31-23 04:30PM	DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
04:30PM	Loading…
Oct-27-23 04:30PM	DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-16-23 02:00AM	DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer (GlobeNewswire)
Oct-05-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (GlobeNewswire)
Sep-05-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire) +11.46% -5.71%
Jul-31-23 04:25PM	DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results (GlobeNewswire) -6.33% +8.78%
Jul-25-23 04:30PM	DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update (GlobeNewswire)
Jul-19-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (GlobeNewswire)
Jul-10-23 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jun-16-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (GlobeNewswire)
Jun-08-23 04:30PM	DBV Technologies to Participate in Upcoming EAACI Congress 2023 (GlobeNewswire)
Jun-06-23 05:00PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
May-10-23 05:30PM	DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin Peanut in Toddlers (GlobeNewswire) +12.12%
May-09-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
May-04-23 04:30PM	DBV Technologies Reports First Quarter 2023 Financial Results (GlobeNewswire) +5.77%
Apr-19-23 05:09PM	DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 3 Years After Receiving Pre-BLA Responses from FDA (GlobeNewswire)
Apr-12-23 04:30PM	DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting (GlobeNewswire)
Mar-24-23 04:30PM	Ordinary and Extraordinary General Meeting of April 12, 2023 (GlobeNewswire)
Mar-13-23 01:30AM	DBV Technologies Update (GlobeNewswire)
Mar-07-23 04:30PM	DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 7 Years Old (GlobeNewswire) +14.57%
Mar-02-23 05:30PM	DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document (GlobeNewswire) -5.52% +5.11%
04:30PM	DBV Technologies Reports Full Year 2022 Financial Results and Business Update (GlobeNewswire)
Feb-27-23 01:30AM	DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023 (GlobeNewswire)
Feb-21-23 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2023 Congress (GlobeNewswire)
Feb-10-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-23-23 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jan-04-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022 (GlobeNewswire)
Dec-23-22 01:30AM	DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial (GlobeNewswire) +22.03%
Dec-08-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (GlobeNewswire)
Nov-22-22 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire) +5.34%
Nov-09-22 01:30AM	DBV Technologies to Highlight New Clinical Data at ACAAI 2022 (GlobeNewswire)
Nov-03-22 04:30PM	DBV Technologies Reports Third Quarter Financial Results and Business Update (GlobeNewswire)
Oct-31-22 04:30PM	DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update (GlobeNewswire)
Oct-20-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (GlobeNewswire)
Oct-03-22 04:30PM	DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors (GlobeNewswire)
Sep-21-22 05:45PM	DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial (GlobeNewswire) -7.24%
Sep-07-22 04:30PM	DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years (GlobeNewswire)
Sep-02-22 04:30PM	DBV Technologies to Present at Upcoming Investor Conferences (GlobeNewswire) +12.95% +7.80%
Aug-10-22 04:50PM	Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space (GlobeNewswire)
Aug-01-22 04:30PM	DBV Technologies Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-27-22 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire) +5.83%
Jul-20-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (GlobeNewswire) +6.99%
Jun-28-22 06:15PM	DBV Technologies to Participate in Upcoming EAACI 2022 Congress (GlobeNewswire)
Jun-16-22 01:30AM	DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York (GlobeNewswire)
Jun-09-22 02:55AM	DBV Technologies Announces Private Placement Financing of $194 Million (GlobeNewswire) +79.56%
Jun-07-22 04:30PM	DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers (GlobeNewswire) +18.30%
May-17-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (GlobeNewswire) +5.74%
May-12-22 04:30PM	DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting (GlobeNewswire)
May-04-22 07:30PM	DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) (GlobeNewswire) +5.51%
May-02-22 05:00PM	DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq (GlobeNewswire) +7.36% -8.30%
04:00PM	DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-25-22 07:30PM	Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments (GlobeNewswire)
04:30PM	DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments (GlobeNewswire)
Apr-21-22 04:30PM	Ordinary and Extraordinary General Meeting of May 12, 2022 (GlobeNewswire)
Apr-14-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022 (GlobeNewswire)
Mar-14-22 04:30PM	DBV Technologies to Present at the Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-11-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022 (GlobeNewswire)
Mar-09-22 04:30PM	DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document (GlobeNewswire) +5.34%
Mar-03-22 04:15PM	DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates (GlobeNewswire) +34.62% -23.43%
Feb-24-22 04:30PM	DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022 (GlobeNewswire)
Feb-22-22 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2022 Congress (GlobeNewswire) -5.04%
Feb-14-22 04:30PM	DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-09-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022 (GlobeNewswire)
Jan-21-22 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire) -6.37%
Jan-18-22 05:38PM	First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ... (GuruFocus.com)
01:38PM	Henry James International Management Inc. ... (GuruFocus.com)
Jan-12-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (GlobeNewswire)
Jan-07-22 01:30AM	DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference (GlobeNewswire)
Dec-20-21 04:15PM	DBV Technologies Provides Update on Investigational Viaskin Peanut (GlobeNewswire) -48.52%
Dec-10-21 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2021 (GlobeNewswire)
Nov-24-21 01:30AM	DBV Technologies to Participate in an Upcoming Investor Conference (GlobeNewswire)

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mohideen Pharis	Chief Medical Officer	Jul 29 '24	Sale	0.98	1,785	1,749	79,367	Jul 31 05:32 PM
Mohideen Pharis	Chief Medical Officer	May 24 '24	Sale	1.36	660	898	81,152	May 29 04:15 PM
Mohideen Pharis	Chief Medical Officer	May 22 '24	Sale	1.38	382	527	81,812	May 29 04:15 PM
Tasse Daniel	CHIEF EXECUTIVE OFFICER	Mar 08 '24	Buy	0.83	17,094	14,188	17,094	Mar 11 04:15 PM
Ndu Adora	Director	Feb 06 '24	Buy	0.89	1,825	1,624	1,825	Feb 08 05:02 PM
Mohideen Pharis	Chief Medical Officer	Nov 22 '23	Sale	1.74	2,245	3,906	82,194	Dec 19 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DBVT

DBV Technologies ADR

Upgrade your FINVIZ experience